Goldim José Roberto
Universidade Federal do Rio Grande do Sul (UFRGS), Hospital de Clínicas de Porto Alegre (HCPA), e Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Faculdade de Medicina, Brasil.
Rev Panam Salud Publica. 2008 Mar;23(3):198-206. doi: 10.1590/s1020-49892008000300007.
This article describes the methodological, regulatory, and ethical aspects of the different therapeutic uses of investigational drugs--research extension, compassionate use, and expanded access. Worldwide, the principle challenges of this kind of treatment are: setting minimum quality standards for researchers, as well as institutions, so that projects can include drugs at various stages of development; training of evaluation and assessment committees on the methodological, regulatory, and ethical aspects of new drug research; clearly outlining the relationship between researchers and funding organizations and between researchers and study participants; and understanding the opposition to the recent proposal to enable drug manufacturers to charge for drugs used in research studies.
本文描述了研究性药物不同治疗用途(研究扩展、同情用药和扩大可及性)的方法学、监管和伦理方面。在全球范围内,这类治疗面临的主要挑战包括:为研究人员以及机构设定最低质量标准,以便项目能够纳入处于不同研发阶段的药物;就新药研究的方法学、监管和伦理方面对评估委员会进行培训;明确界定研究人员与资助机构之间以及研究人员与研究参与者之间的关系;以及理解对近期允许药品制造商对研究性用药收费提案的反对意见。